13F Holdings
中文EN

YARW Yarrow Bioscience, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1566044 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-2.1%
TTM net income YoY-35.6%
TTM EPS YoY-1,140.7%
Revenue 3-yr CAGR-12.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-8,949.6%
Net margin-8,097.7%
FCF margin—
EBITDA margin—

Returns

ROE-67.8%
ROA-58.7%
ROIC (approx.)-108.4%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.60x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio1.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$570,000$501,000$424,000$477,000$931,000
Cost of revenue————$3.35M
Gross profit————-$2.42M
R&D expense$19.24M$30.95M$16.31M$18.39M$19.54M
SG&A expense$11.08M$13.19M$13.38M$16.39M$20.30M
Operating income-$29.75M-$43.64M-$29.26M-$34.30M-$38.91M
Interest expense———$0$5.61M
Pretax income-$26.73M-$39.80M-$27.87M-$33.93M-$44.66M
Income tax$4,000$4,000$0$13,000-$448,000
Net income-$26.48M-$39.83M-$28.45M-$23.21M-$73.33M
EBITDA-$29.73M-$43.63M-$29.26M-$34.22M-$38.80M
EPS (basic)-0.62-0.93-2.78-7.28-25.64
EPS (diluted)-0.62-0.93-2.78-7.28-25.64
Weighted avg. shares (diluted)42.77M42.59M10.27M3.19M2.86M
Balance sheet
Cash & equivalents$99.99M$19.93M$30.67M$30.98M$42.85M
Short-term investments$4.98M$41.59M$62.63M$0$0
Receivables———$173,000$7.58M
Inventory————$7.29M
Current assets$100.00M$64.44M$95.96M$38.27M$63.19M
PP&E, net$0$113,000$0$0$354,000
Total assets$100.41M$66.91M$97.69M$40.76M$67.05M
Current liabilities$71.55M$14.82M$7.54M$9.35M$18.41M
Long-term debt$0$0$0$0$0
Total debt$0$0$0$0$0
Total liabilities$71.55M$14.82M$8.95M$9.35M$18.41M
Shareholders' equity-$70.99M$52.09M$88.73M$31.20M$48.64M
Net debt-$99.99M-$19.93M-$30.67M-$30.98M-$42.85M
Shares outstanding3.05M14.83M14.10M3.23M2.98M
Cash flow statement
Operating cash flow-$33.12M-$33.97M-$25.34M-$29.20M-$56.37M
Capital expenditure$0$117,000$0—$0
Free cash flow-$33.12M-$34.09M-$25.34M—-$56.37M
Investing cash flow$37.37M$23.36M-$57.35M$15.67M$1.03M
Financing cash flow-$143,000-$141,000$82.39M$1.65M$39.78M
Depreciation & amortization$23,000$4,000$0$72,000$109,000
Stock-based compensation$2.31M$3.30M$3.31M$4.30M$8.08M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.